Mepolizumab
Based on 1 Customer Validation
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.4%
- CAS No.: 196078-29-2
- Masse moléculaire:146.24 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-5
In Vitro
Mepolizumab shows nearly linear PK after intravenous administration over a 6000-fold dose range (0.05-300 mg/kg), inhibiting eosinophil proliferation with an IC50 of 1.43 mg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pharmacokinetic analysis of mepolizumab in cynomolgus monkeys[1]
| Route | Dose (mg/kg) | Cmax (μg/mL) | AUC0-INF_obs (μg·h/mL) | T1/2 (days) | Clobs (mL·h/kg) | Vss_obs (mL/kg) |
| i.v. | 300 | 6700 | 1405000 | 11.7 | 0.217 | 74.6 |
| i.v. | 3 | 89.1 | 14600 | 11.2 | 0.208 | 82.1 |